1e
19
1
49
2
2
18
1b
1d
18
3e
53
1d
2 29
1d
25
Robert H. Vonderheide, MD, DPhil
78
53
John H. Glick Abramson Cancer Center Professor
28
88
3
5f
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
6e
Investigator, Abramson Family Cancer Research Institute
84
Member, Abramson Cancer Center, University of Pennsylvania School of Medicine
75
Director, Abramson Cancer Center , University of Pennsylvania
88
Director, Abramson Family Cancer Research Institute , University of Pennsylvania
8a
Vice Dean, Cancer Programs, University of Pennsylvania Perelman School of Medicine
82
Vice President, Cancer Programs , University of Pennsylvania Health System
11
Department: Medicine
4
1
23
1f
Graduate Group Affiliations
8
b
-
6b
- Cell and Molecular Biology 5c
- Immunology e
1d
46
Contact information
3f
4
3
3
1d
3f
12 South Pavilion
39 3400 Civic Center Blvd
Philadelphia, PA 19104
26
39 3400 Civic Center Blvd
Philadelphia, PA 19104
2e
Office: 215-662-3929
32 Fax: 215-573-2652
32 Lab: 215-746-2846
18
7b
32 Fax: 215-573-2652
32 Lab: 215-746-2846
18
Email:
rhv@upenn.edu
12
rhv@upenn.edu
18
Publications
23 a
3
2
29
23 a
Links
9c Search PubMed for articles
4b Cell and Molecular Biology graduate group, University of Pennsylvania School of Medicine
c6 Hematology Oncology Division, Department of Medicine, University of Pennsylania School of Medicine
c
4
b
1f
9c Search PubMed for articles
4b Cell and Molecular Biology graduate group, University of Pennsylvania School of Medicine
c6 Hematology Oncology Division, Department of Medicine, University of Pennsylania School of Medicine
c
13
Education:
21 8 BSc 21 (Chemical Engineering) c
31 University of Notre Dame, 1985.
21 a DPhil 17 (Immunology) c
2a Oxford University, 1989.
21 7 MD c
2f Harvard Medical School, 1993.
c
3
3
3
3
8a
Permanent link21 8 BSc 21 (Chemical Engineering) c
31 University of Notre Dame, 1985.
21 a DPhil 17 (Immunology) c
2a Oxford University, 1989.
21 7 MD c
2f Harvard Medical School, 1993.
c
2 29
21
1e
1d
24
5e
224 The Vonderheide laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer. The chief hypothesis is that successful approaches in tumor immunotherapy will need to (a) optimize target antigens with regard to clinical applicability and risk of antigen loss, (b) repair host immuno-incompetence in antigen presentation and T cell function, and (c) circumvent immuno-suppressive factors of the tumor and tumor microenvironment.
8
18 RESEARCH DETAILS
301 Dr. Vonderheide’s basic research includes deciphering the immunobiology of novel genetically engineered mouse models of cancer, including the regulation of immune surveillance and the tumor microenvironment by CD40 and other pathways, and with a focus on pancreatic cancer, breast cancer, and melanoma. His translational work tests novel approaches such as vaccines, antibodies, and adoptive T cells for the treatment of patients with melanoma, pancreatic cancer and other cancers. He has studied ‘universal’ tumor antigens, immune effects of radiation, and immune modulatory pathways involving CD40, GM-CSF, PD-1, CTLA-4, and CD25. Publications include those in high-impact journals such as Nature, Science, Cell, and the New England Journal of Medicine.
8
8
1c LABORATORY PERSONNEL
8
25 Robert Vonderheide, MD, DPhil
5d Director, Abramson Cancer Center; John H. Glick MD Abramson Cancer Center's Professor
8
34 Nune Markosyan, MD, PhD, Laboratory Director
8
32 Katelyn Byrne, PhD, Instructor in Medicine
8
35 Mark Diamond, MD, PhD, Instructor in Medicine
8
2c Adham Bear, MD, PhD, Clinical Fellow
8
26 Alex Morrison, MD, TRM Student
8
34 Bereket Gebregziabher, undergraduate student
8
3a Austin Huffman, Graduate Student (PhD, Immunology)
8
2e Jeffrey Lin, Graduate Student (MD/PhD)
8
33 Andrew Rech, Post-doctoral Scholar (MD/PhD)
8
2e Lee Richman, Graduate Student (MD/PhD)
8
4a Mary Beth McAndrew, Administrator, 215-662-3929; mcandrem@upenn.edu
65
1a 29
27
Description of Research Expertise
23 RESEARCH INTERESTS224 The Vonderheide laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer. The chief hypothesis is that successful approaches in tumor immunotherapy will need to (a) optimize target antigens with regard to clinical applicability and risk of antigen loss, (b) repair host immuno-incompetence in antigen presentation and T cell function, and (c) circumvent immuno-suppressive factors of the tumor and tumor microenvironment.
8
18 RESEARCH DETAILS
301 Dr. Vonderheide’s basic research includes deciphering the immunobiology of novel genetically engineered mouse models of cancer, including the regulation of immune surveillance and the tumor microenvironment by CD40 and other pathways, and with a focus on pancreatic cancer, breast cancer, and melanoma. His translational work tests novel approaches such as vaccines, antibodies, and adoptive T cells for the treatment of patients with melanoma, pancreatic cancer and other cancers. He has studied ‘universal’ tumor antigens, immune effects of radiation, and immune modulatory pathways involving CD40, GM-CSF, PD-1, CTLA-4, and CD25. Publications include those in high-impact journals such as Nature, Science, Cell, and the New England Journal of Medicine.
8
8
1c LABORATORY PERSONNEL
8
25 Robert Vonderheide, MD, DPhil
5d Director, Abramson Cancer Center; John H. Glick MD Abramson Cancer Center's Professor
8
34 Nune Markosyan, MD, PhD, Laboratory Director
8
32 Katelyn Byrne, PhD, Instructor in Medicine
8
35 Mark Diamond, MD, PhD, Instructor in Medicine
8
2c Adham Bear, MD, PhD, Clinical Fellow
8
26 Alex Morrison, MD, TRM Student
8
34 Bereket Gebregziabher, undergraduate student
8
3a Austin Huffman, Graduate Student (PhD, Immunology)
8
2e Jeffrey Lin, Graduate Student (MD/PhD)
8
33 Andrew Rech, Post-doctoral Scholar (MD/PhD)
8
2e Lee Richman, Graduate Student (MD/PhD)
8
4a Mary Beth McAndrew, Administrator, 215-662-3929; mcandrem@upenn.edu
65
Description of Clinical Expertise
5b Medical Oncology and Experimental Therapeutics, in particular Immunotherapy1a 29
23
e5 Diamond MS, Lin JH, Vonderheide, RH. : Site-dependent immune escape of highly antigenic tumors without immunoediting. Cancer Immunol Res. 9: 877-890, 2021.
1e2 Reiss KA, Mick R, O’Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izqur N, Hannan ZM, Tondon R, Nathanson K, Vonderheide RH, Wattenberg MM, Beatty G, Domchek SM. : Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 39: 2497-2505, 2021.
28b Sun L, Surya S, Goodman NG, Le AN, Kelly G, Olutosin O, Desai H, Zheng C, DeLuca S, Good ML, Hussain J, Jeffries SD, Kry YR, Kugler EM, Mansour M, Ndicu J, Osei-Akoto A, Prior T, Pundock SL, Varughese LA, Weaver J, Doucette A, Dudek S, Verma SS, Gouma S, Weirick MD, McAllister CM, Bange E, Gabriel P, Ritchie M, Rader DJ, Vonderheide RH, Schuchter LM, Verma A, Maillard I, Mamtani R, Hensley SE, Gross R, Wileyto EP, Huang AC, Maxwell KN, DeMichele A.: SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. JCO Oncol Pract. 2021.
189 Maity A, Mick R, Rengan R, Mitchell TC, Amaravadi RK, Schuchter LM, Pryma DA, Patsch DM, Maity AP, Minn AJ, Vonderheide RH, Lukens JN.: A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. Oncoimmunology 2021.
1cb Reiss KA, Wattenberg MM, Damjanov N, Prechtel Dunphy E, Jacobs-Small M, Lubas MJ, Robinson J, DiCicco L, Garcia-Marcano L, Giannone MA, Karasic TB, Furth EE, Carpenter EL, Wojcieszynski AP, Vonderheide RH, Beatty GL, Ben-Josef E. : A pilot study of galunisertib plus stereotactic body radiography in patients with advanced hepatocellular carcinoma. Mol Cancer Thera. 20: 389-397, 2021.
352 Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield Fl, Owoyemi O, Naik K, Zheng C Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum, RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollet S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella LA, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP, Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer NJ, DeMichele AM, Vardhana SA, Mamtani R, Huang AC.: CD8 + T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 27: 1280-1289, 2021.
24b Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O’Hara MH, Liudahl SM, Newcomb CW, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman A, Vayrynen SA, Costa AD, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH.: Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin. Cancer Res. 27: 4574-4586, 2021.
156 Yang F, He Z, Duan H, Zhang D, Li J, Yang H, Dorsey JF, Zou W, Nabavizadeh SA, Bagley SJ, Abdullah K, Brem S, Zhang L, Xu X, Byrne KT, Vonderheide RH, Gong Y, Fan Y. : Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun. 12, 2021.
2b5 O’Hara MH, O’Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch L, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lucey VM, Wherry EJ, Ibrahim R, Vonderheide RH: An open-label, multicenter, phase 1b study evaluating the safety and efficacy of CD40 agonistics monoclonal antibody APX005M and chemotherapy with or without nivolumab for the treatment of metastatic pancreatic cancer. Lancet Oncology 22: 118-131, 2021.
2c
7
1d
1f
Selected Publications
15e Sun L, Surya S, Le AN, Desai H, Doucette A, Gabriel P, Ritchie MD, Rader D, Maillard I, Bange E, Huang AC, Vonderheide RH, DeMichele A, Verma A, Mamtani R, Maxwell KN.: Rates of COVID-19-related outcomes in cancer compared with noncancer patients. JNCI Cancer Spectr. 5, 2021.e5 Diamond MS, Lin JH, Vonderheide, RH. : Site-dependent immune escape of highly antigenic tumors without immunoediting. Cancer Immunol Res. 9: 877-890, 2021.
1e2 Reiss KA, Mick R, O’Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izqur N, Hannan ZM, Tondon R, Nathanson K, Vonderheide RH, Wattenberg MM, Beatty G, Domchek SM. : Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 39: 2497-2505, 2021.
28b Sun L, Surya S, Goodman NG, Le AN, Kelly G, Olutosin O, Desai H, Zheng C, DeLuca S, Good ML, Hussain J, Jeffries SD, Kry YR, Kugler EM, Mansour M, Ndicu J, Osei-Akoto A, Prior T, Pundock SL, Varughese LA, Weaver J, Doucette A, Dudek S, Verma SS, Gouma S, Weirick MD, McAllister CM, Bange E, Gabriel P, Ritchie M, Rader DJ, Vonderheide RH, Schuchter LM, Verma A, Maillard I, Mamtani R, Hensley SE, Gross R, Wileyto EP, Huang AC, Maxwell KN, DeMichele A.: SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. JCO Oncol Pract. 2021.
189 Maity A, Mick R, Rengan R, Mitchell TC, Amaravadi RK, Schuchter LM, Pryma DA, Patsch DM, Maity AP, Minn AJ, Vonderheide RH, Lukens JN.: A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. Oncoimmunology 2021.
1cb Reiss KA, Wattenberg MM, Damjanov N, Prechtel Dunphy E, Jacobs-Small M, Lubas MJ, Robinson J, DiCicco L, Garcia-Marcano L, Giannone MA, Karasic TB, Furth EE, Carpenter EL, Wojcieszynski AP, Vonderheide RH, Beatty GL, Ben-Josef E. : A pilot study of galunisertib plus stereotactic body radiography in patients with advanced hepatocellular carcinoma. Mol Cancer Thera. 20: 389-397, 2021.
352 Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield Fl, Owoyemi O, Naik K, Zheng C Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum, RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollet S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella LA, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP, Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer NJ, DeMichele AM, Vardhana SA, Mamtani R, Huang AC.: CD8 + T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 27: 1280-1289, 2021.
24b Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O’Hara MH, Liudahl SM, Newcomb CW, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman A, Vayrynen SA, Costa AD, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH.: Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin. Cancer Res. 27: 4574-4586, 2021.
156 Yang F, He Z, Duan H, Zhang D, Li J, Yang H, Dorsey JF, Zou W, Nabavizadeh SA, Bagley SJ, Abdullah K, Brem S, Zhang L, Xu X, Byrne KT, Vonderheide RH, Gong Y, Fan Y. : Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun. 12, 2021.
2b5 O’Hara MH, O’Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch L, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lucey VM, Wherry EJ, Ibrahim R, Vonderheide RH: An open-label, multicenter, phase 1b study evaluating the safety and efficacy of CD40 agonistics monoclonal antibody APX005M and chemotherapy with or without nivolumab for the treatment of metastatic pancreatic cancer. Lancet Oncology 22: 118-131, 2021.
2c